SG10201914069SA - Compositions and methods for tcr reprogramming using fusion proteins - Google Patents

Compositions and methods for tcr reprogramming using fusion proteins

Info

Publication number
SG10201914069SA
SG10201914069SA SG10201914069SA SG10201914069SA SG10201914069SA SG 10201914069S A SG10201914069S A SG 10201914069SA SG 10201914069S A SG10201914069S A SG 10201914069SA SG 10201914069S A SG10201914069S A SG 10201914069SA SG 10201914069S A SG10201914069S A SG 10201914069SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
fusion proteins
reprogramming
tcr
Prior art date
Application number
SG10201914069SA
Inventor
Patrick Baeuerle
Gregory Sieczkiewicz
Robert Hofmeister
Original Assignee
Tcr2 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914069S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tcr2 Therapeutics Inc filed Critical Tcr2 Therapeutics Inc
Publication of SG10201914069SA publication Critical patent/SG10201914069SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG10201914069SA 2015-05-18 2016-05-18 Compositions and methods for tcr reprogramming using fusion proteins SG10201914069SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562163342P 2015-05-18 2015-05-18

Publications (1)

Publication Number Publication Date
SG10201914069SA true SG10201914069SA (en) 2020-03-30

Family

ID=57320750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201914069SA SG10201914069SA (en) 2015-05-18 2016-05-18 Compositions and methods for tcr reprogramming using fusion proteins

Country Status (20)

Country Link
US (5) US10442849B2 (en)
EP (3) EP3466967A1 (en)
JP (4) JP2018515123A (en)
KR (1) KR20180029201A (en)
CN (2) CN114634943A (en)
AU (2) AU2016264323B2 (en)
BR (1) BR112017024757A2 (en)
CA (1) CA2986254A1 (en)
DK (1) DK3298033T4 (en)
EA (2) EA202090931A3 (en)
ES (1) ES2819976T5 (en)
FI (1) FI3298033T4 (en)
HK (1) HK1252643A1 (en)
HU (1) HUE051661T2 (en)
IL (2) IL303905A (en)
MX (1) MX2017014822A (en)
PL (1) PL3298033T5 (en)
PT (1) PT3298033T (en)
SG (1) SG10201914069SA (en)
WO (1) WO2016187349A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
WO2017004252A1 (en) * 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
MX2018001568A (en) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Bispecific car t-cells for solid tumor targeting.
WO2017059796A1 (en) * 2015-10-08 2017-04-13 Shanghai Sidansai Biotechnology Co., Ltd Activation and expansion of t cells
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10086055B2 (en) * 2016-06-01 2018-10-02 Promab Biotechnologies, Inc. Adherent cancer cell line expressing a hematological tumor antigen
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11307205B2 (en) 2016-09-19 2022-04-19 University Of Southern California Non-radioactive cytotoxicity assays
WO2018064076A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
PL3445787T3 (en) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2020513754A (en) * 2016-12-21 2020-05-21 ティーシーアール２ セラピューティクス インク． T cells engineered for cancer treatment
CN116120454A (en) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 Humanized anti-CD 19 antibodies and their use with chimeric antigen receptors
EP3577134A1 (en) * 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018166589A1 (en) 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
CN110741016A (en) * 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
JP7295030B2 (en) 2017-04-26 2023-06-20 ユーリカ セラピューティックス， インコーポレイテッド Construct that specifically recognizes glypican 3 and use thereof
PT3618842T (en) * 2017-05-01 2024-01-12 Juno Therapeutics Inc Combination of a cell therapy and an immunomodulatory compound
MX2019013514A (en) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology.
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
MX2020007266A (en) 2017-09-26 2020-09-07 Cero Therapeutics Inc Chimeric engulfment receptor molecules and methods of use.
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR102160061B1 (en) * 2018-02-01 2020-09-29 난징 아이에이에스오 바이오테라퓨틱스 컴퍼니, 리미티드 Chimeric antigen receptor (CAR) binding to BCMA and uses thereof
US11266690B2 (en) 2018-02-01 2022-03-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
EP3749349A4 (en) * 2018-02-10 2021-11-24 Berkeley Lights, Inc. Mutant idh1 specific t cell receptor
EP3749687A4 (en) 2018-02-11 2021-12-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
KR20200144093A (en) 2018-02-17 2020-12-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Compositions and methods for membrane protein delivery
WO2019173693A1 (en) * 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2020010235A (en) 2018-03-28 2020-10-28 Cero Therapeutics Inc Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof.
WO2019191340A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
US20210087251A1 (en) 2018-03-28 2021-03-25 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
KR20210008502A (en) 2018-05-11 2021-01-22 크리스퍼 테라퓨틱스 아게 Methods and compositions for treating cancer
JP7447388B2 (en) * 2018-07-13 2024-03-12 ナンジン レジェンド バイオテック カンパニー，リミテッド Coreceptor systems for the treatment of infectious diseases
SG11202100838QA (en) * 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
CN109735558B (en) * 2018-12-12 2022-04-15 中南大学 Recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application
CN113164626A (en) * 2019-01-14 2021-07-23 南京传奇生物科技有限公司 Chimeric receptor polypeptides and uses thereof
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
EP3715368A1 (en) 2019-03-28 2020-09-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
WO2020201527A1 (en) 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
WO2020219563A1 (en) * 2019-04-22 2020-10-29 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112021021542A2 (en) 2019-04-30 2022-04-19 Crispr Therapeutics Ag Allogeneic cell therapy of b-cell malignancies using genetically modified t-cells that target cd19
US20220252594A1 (en) * 2019-05-28 2022-08-11 The University Of Vermont And State Agricultural College Gamma-delta t cell ligands for cancer immunotherapy
CN114729383A (en) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 Recombinant AD35 vectors and related gene therapy improvements
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20240058446A1 (en) 2019-10-03 2024-02-22 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
CN110964122B (en) * 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T cell receptor fusion proteins and uses thereof
EP4126962A1 (en) * 2020-04-01 2023-02-08 Medigene Immunotherapies GmbH Cd3-fusion protein and uses thereof
WO2022020720A1 (en) * 2020-07-24 2022-01-27 TCR2 Therapeutics Inc. Compositions and methods for treating cancer
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN112521513B (en) * 2020-12-15 2021-08-24 青岛西凯生物技术有限公司 Chimeric Antigen Receptor (CAR) targeting CD19 and application thereof
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
TW202241479A (en) 2020-12-30 2022-11-01 美商安迅生物製藥公司 Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
WO2022174172A1 (en) * 2021-02-15 2022-08-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
WO2022177966A1 (en) * 2021-02-16 2022-08-25 TCR2 Therapeutics Inc. Compositions and methods for the treatment of hiv
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2022192286A1 (en) * 2021-03-09 2022-09-15 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and rna interference
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2023010097A1 (en) 2021-07-28 2023-02-02 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2023010436A1 (en) * 2021-08-05 2023-02-09 卡瑞济(北京)生命科技有限公司 Tcr expression construct, and preparation method therefor and use thereof
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023091910A1 (en) 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009390A (en) 1910-04-18 1911-11-21 Miehle Printing Press & Mfg Manufacture of printing-plates.
US1035847A (en) 1910-05-23 1912-08-20 William P Bettendorf Means for cushioning the bodies of railway-cars.
US1020828A (en) 1911-12-11 1912-03-19 William A Rees Electric washing-machine.
US1044284A (en) 1912-04-29 1912-11-12 Gen Electric Heating device.
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5906936A (en) * 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
AU5303700A (en) 1999-05-27 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunoconjugates having high binding affinity
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
ES2302726T3 (en) 2000-02-24 2008-08-01 Invitrogen Corporation STIMULATION AND SIMULTANEOUS CONCENTRATION OF CELLS.
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
AU2001271589A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
WO2003068822A2 (en) 2002-02-13 2003-08-21 Micromet Ag De-immunized (poly)peptide constructs
DE10244457A1 (en) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Process for the rational mutagenesis of alpha / beta T-cell receptors and corresponding mutated MDM2 protein-specific alpha / beta T-cell receptors
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7251470B2 (en) 2003-06-25 2007-07-31 Nokia Corporation Emergency response system with personal emergency device
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
ES2458636T3 (en) 2003-08-18 2014-05-06 Medimmune, Llc Humanization of antibodies
JP2007528723A (en) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド Antibody humanization
EP2292664B1 (en) 2003-10-16 2016-11-23 Amgen Research (Munich) GmbH Multispecific deimmunized CD3-binders
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc Novel tetravalent bispecific antibody
WO2006018833A2 (en) 2004-08-16 2006-02-23 Tadiran Spectralink Ltd. A wearable device, system and method for measuring a pulse while a user is in motion
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP4949373B2 (en) 2005-03-10 2012-06-06 モルフォテック、インク． Anti-mesothelin antibody
CA2607305A1 (en) 2005-05-12 2006-11-23 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
KR20140053410A (en) 2005-08-19 2014-05-07 아보트 러보러터리즈 Dual variable domain immunoglobulin and uses thereof
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
ES2663323T3 (en) 2007-03-30 2018-04-12 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands in T lymphocytes transferred in an adoptive manner
NZ585551A (en) 2007-11-26 2012-06-29 Bayer Schering Pharma Ag Anti-mesothelin antibodies and uses therefor
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR20090092900A (en) 2008-02-28 2009-09-02 신준호 Safety and Care System for Child and Feeble Person
US20090322513A1 (en) 2008-06-27 2009-12-31 Franklin Dun-Jen Hwang Medical emergency alert system and method
ES2961498T3 (en) 2008-08-26 2024-03-12 Hope City Method and compositions for enhanced performance of anti-tumor effect of T cells
AU2009299791B2 (en) 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
HUE028175T2 (en) 2008-11-07 2016-12-28 Amgen Res (Munich) Gmbh Treatment of acute lymphoblastic leukemia
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2010104949A2 (en) * 2009-03-10 2010-09-16 Biogen Idec Ma Inc. Anti-bcma antibodies
WO2010124188A1 (en) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US20130066283A1 (en) 2009-10-23 2013-03-14 Nexisvision, Inc. Corneal Denervation for Treatment of Ocular Pain
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
LT2361936T (en) 2010-02-25 2016-09-12 Affimed Gmbh Antigen-binding molecule and uses thereof
PL2552959T3 (en) 2010-03-26 2017-08-31 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
US9493740B2 (en) 2010-09-08 2016-11-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered GD2-specific T cells
EP3372244A3 (en) 2010-10-27 2018-10-24 Baylor College of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
HUE027678T2 (en) 2010-10-27 2016-11-28 Amgen Res (Munich) Gmbh Means and methods for treating dlbcl
ES2657970T3 (en) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit / human ROR1 antibodies
DK3214091T3 (en) 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
TWI477513B (en) 2010-12-20 2015-03-21 建南德克公司 Anti-mesothelin antibodies and immunoconjugates
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2665521A4 (en) 2011-01-18 2014-09-03 Univ Pennsylvania Compositions and methods for treating cancer
ES2588730T3 (en) 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Exhausted cell preparations in regards to TCRalfa / beta
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
MX2014003176A (en) 2011-09-16 2015-08-05 Univ Pennsylvania Rna engineered t cells for the treatment of cancer.
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
ES2774160T3 (en) 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EA201491572A1 (en) 2012-02-22 2014-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания COMPOSITIONS AND METHODS OF OBTAINING SUSTAINABLE POPULATION OF T-CELLS USED FOR THE TREATMENT OF MALIGNANT NORMATION
CA2864489C (en) * 2012-02-22 2023-08-08 The Trustees Of The University Of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
CA2869562C (en) * 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
MX370265B (en) 2012-05-25 2019-12-09 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy.
BR112015000638A2 (en) 2012-07-13 2017-08-08 Univ Pennsylvania isolated nucleic acid sequence, cell, methods for stimulating a cell-mediated immune response to a target cell or tissue population in a mammal, for providing antitumor immunity in a mammal, for treating a mammal having a disease, disorder or condition associated with high expression of a tumor antigen
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania Epitope spreading associated with car t-cells
BR112015000505A2 (en) 2012-07-13 2017-06-27 Univ Pennsylvania method of analyzing a genetically modified t-cell to detect a contaminant
HUE053439T2 (en) 2012-08-20 2021-06-28 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
CN104955845B (en) 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) Mesothelin antibody and cause the active method of effective antitumour
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
EP3597215A1 (en) 2012-10-02 2020-01-22 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
CA2892059C (en) 2012-11-21 2023-02-14 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
US10077315B2 (en) 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
EP3985028A1 (en) 2013-02-06 2022-04-20 Celgene Corporation Modified t lymphocytes having improved specificity
CA2901115A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of California Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof
EP2958942B1 (en) * 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
JP6499087B2 (en) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー Bispecific T cell activation antigen binding molecule
RU2680010C2 (en) 2013-02-26 2019-02-14 Мемориал Слоан-Кеттеринг Кэнсер Сентер Compositions and methods of immunotherapy
JP6480874B2 (en) 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Gene correction based on TALEN
EP3447072A3 (en) 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
NZ712693A (en) 2013-03-15 2021-07-30 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
EP2970372B1 (en) 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
EP2997141B1 (en) 2013-05-13 2022-10-12 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
ES2883131T3 (en) 2013-05-29 2021-12-07 Cellectis Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
DK3004337T3 (en) 2013-05-29 2017-11-13 Cellectis Method for constructing T cells for immunotherapy using RNA-guided Cas nuclease system
BR112016000666A2 (en) 2013-07-12 2017-10-03 Zymeworks Inc BISPECIFIC CD3 AND CD19 ANTIGEN BINDING CONSTRUCTS
AU2014296059B2 (en) 2013-08-02 2020-12-10 The Regents Of The University Of California Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20150238631A1 (en) 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
HUE052573T2 (en) 2013-12-20 2021-05-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
JP6793902B2 (en) 2013-12-20 2020-12-02 ノバルティス アーゲー Adjustable chimeric antigen receptor
ES2923641T3 (en) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Immunoglobulin with Fabs in tandem and uses thereof
EP3094354B1 (en) 2014-01-14 2018-10-17 Cellectis Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
ES2963718T3 (en) * 2014-01-21 2024-04-01 Novartis Ag Antigen-presenting capacity of CAR-T cells enhanced by co-introduction of co-stimulatory molecules
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
EP3097123A1 (en) 2014-01-24 2016-11-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
KR20220119176A (en) 2014-02-04 2022-08-26 카이트 파마 인코포레이티드 Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
WO2015123642A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
PT3105317T (en) 2014-02-14 2019-02-27 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US10196608B2 (en) 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
CN106029098A (en) 2014-02-25 2016-10-12 免疫医疗公司 Humanized RFB4 anti-CD22 antibody
KR101605421B1 (en) 2014-03-05 2016-03-23 국립암센터 A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP6817069B2 (en) 2014-04-25 2021-01-20 ブルーバード バイオ， インコーポレイテッド An improved way to manufacture adoptive cell therapies
DK3689899T3 (en) 2014-04-25 2021-11-22 2Seventy Bio Inc CHIMARY MND PROMOTER ANTIGEN RECEPTORS
CN107074929B (en) 2014-05-02 2021-09-03 宾夕法尼亚大学董事会 Compositions and methods for chimeric autoantibody receptor T cells
WO2015179801A1 (en) 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
WO2015177349A1 (en) 2014-05-23 2015-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- egfr conformational single domain antibodies and uses thereof
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
CN107075483A (en) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 The engineered cell treated for adoptive cellular
CN106687483B (en) * 2014-07-21 2020-12-04 诺华股份有限公司 Treatment of cancer using humanized anti-BCMA chimeric antigen receptors
MX2017001079A (en) 2014-07-24 2017-09-12 Bluebird Bio Inc Bcma chimeric antigen receptors.
DK3453406T3 (en) 2014-07-29 2021-07-12 Cellectis ROR1 (NTRKR1) -specific chimeric antigen receptors for cancer immunotherapy
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016022900A1 (en) 2014-08-07 2016-02-11 Northwestern University Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
WO2016022994A2 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
SG11201701111SA (en) 2014-08-12 2017-03-30 Anthrogenesis Corp Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
MA40595A (en) 2014-09-09 2021-05-26 Unum Therapeutics CHEMERICAL RECEPTORS AND USES OF THEM IN IMMUNE THERAPY
KR20170057351A (en) 2014-09-19 2017-05-24 시티 오브 호프 132 costimulatory chimeric antigen receptor t cells targeting il13r2
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
JP2017531430A (en) 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Method for modulating the activity of immune cells induced by CAR
CN117427091A (en) 2014-10-20 2024-01-23 朱诺治疗学股份有限公司 Compositions and methods for administration in adoptive cell therapy
CN107106670A (en) † 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 Method and composition for the T cell of modification
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
PL3215601T3 (en) 2014-11-05 2020-11-02 Juno Therapeutics, Inc. Methods for transduction and cell processing
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016079081A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
EP3025719B1 (en) 2014-11-26 2018-09-26 Miltenyi Biotec GmbH Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN107206025A (en) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 The method and composition treated for adoptive cellular
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
SI3226897T1 (en) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SG10202007326QA (en) 2014-12-05 2020-08-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
WO2016097231A2 (en) 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
EP3037170A1 (en) 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Multisort cell separation method
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
TWI718118B (en) 2015-01-16 2021-02-11 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for ror1
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN107635578A (en) 2015-02-05 2018-01-26 Stc.Unm 公司 BCR antagonists and method before anti-
EP3253414A4 (en) 2015-02-05 2018-07-11 The University Of Queensland Targeting constructs for delivery of payloads
US20160228547A1 (en) 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
EP3256496B1 (en) 2015-02-12 2020-12-30 University Health Network Chimeric antigen receptors
US20160237407A1 (en) 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
AU2016222887B2 (en) 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
BR112017018770A2 (en) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. reduced immune tolerance induced by pd-l1
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016161415A2 (en) 2015-04-02 2016-10-06 Memorial Sloan Kettering Cancer Center Tnfrsf14/ hvem proteins and methods of use thereof
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
CN115925971A (en) 2015-06-19 2023-04-07 塞巴斯蒂安·科博尔德 PD-1-CD28 fusion protein and application thereof in medicine
CN106519037B (en) 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 Activable Chimerical receptor
ES2920525T3 (en) 2015-10-05 2022-08-05 Prec Biosciences Inc Genetically modified cells comprising a modified human T cell receptor alpha constant region gene
JP7082055B2 (en) 2015-12-22 2022-06-07 ノバルティス アーゲー Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment
CA3012422A1 (en) 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
IL261941B2 (en) 2016-04-01 2023-11-01 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
PL3445787T3 (en) * 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2020513754A (en) 2016-12-21 2020-05-21 ティーシーアール２ セラピューティクス インク． T cells engineered for cancer treatment
CN110741016A (en) 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2019173693A1 (en) 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2019222275A2 (en) 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
SG11202100838QA (en) 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
BR112021003416A2 (en) 2018-08-30 2021-05-18 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins

Also Published As

Publication number Publication date
EA202090931A3 (en) 2020-10-30
EA201792420A1 (en) 2018-04-30
EP3298033A1 (en) 2018-03-28
US10358473B2 (en) 2019-07-23
JP2021176326A (en) 2021-11-11
HK1252643A1 (en) 2019-05-31
BR112017024757A2 (en) 2018-11-13
JP2018515123A (en) 2018-06-14
FI3298033T4 (en) 2023-09-22
IL255697B1 (en) 2023-07-01
PT3298033T (en) 2020-09-22
JP7262535B2 (en) 2023-04-21
EA035618B1 (en) 2020-07-16
WO2016187349A1 (en) 2016-11-24
ES2819976T5 (en) 2024-02-23
CN107995913A (en) 2018-05-04
IL255697B2 (en) 2023-11-01
EA202090931A2 (en) 2020-07-31
MX2017014822A (en) 2018-04-30
PL3298033T3 (en) 2021-02-22
US10358474B2 (en) 2019-07-23
US20200362011A1 (en) 2020-11-19
US20200207828A1 (en) 2020-07-02
DK3298033T4 (en) 2023-10-02
PL3298033T5 (en) 2023-10-30
US11028142B2 (en) 2021-06-08
AU2016264323B2 (en) 2021-02-18
EP3770168A1 (en) 2021-01-27
HUE051661T2 (en) 2021-03-29
AU2016264323A1 (en) 2017-12-14
CA2986254A1 (en) 2016-11-24
US20180244747A1 (en) 2018-08-30
EP3298033B2 (en) 2023-07-12
EP3298033A4 (en) 2018-10-24
US20180251514A1 (en) 2018-09-06
JP2023085509A (en) 2023-06-20
US20230235010A1 (en) 2023-07-27
EP3466967A1 (en) 2019-04-10
JP2021184749A (en) 2021-12-09
CN107995913B (en) 2022-02-11
ES2819976T3 (en) 2021-04-19
US20210206827A9 (en) 2021-07-08
US10442849B2 (en) 2019-10-15
CN114634943A (en) 2022-06-17
JP7047172B2 (en) 2022-04-04
IL303905A (en) 2023-08-01
EP3298033B1 (en) 2020-08-05
AU2016264323A8 (en) 2017-12-21
IL255697A (en) 2018-01-31
AU2021203052A1 (en) 2021-06-10
US20170166622A1 (en) 2017-06-15
KR20180029201A (en) 2018-03-20

Similar Documents

Publication Publication Date Title
HK1252643A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
GB2564823B8 (en) Compositions and methods for TCR reprogramming using fusion proteins
HK1254450A1 (en) Novel fusion polypeptide specific for lag-3 and pd-1
HK1244019A1 (en) Fusion proteins
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
GB201509413D0 (en) Fusion protein
HK1246315A1 (en) Cytokine fusion proteins
SG11202008721SA (en) Compositions and methods for tcr reprogramming using fusion proteins
IL257170B (en) Stable proteins and methods for designing same
SG11202101811VA (en) Compositions and methods for tcr reprogramming using fusion proteins
GB201504691D0 (en) Fusion protein
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
IL297395B1 (en) Btla fusion protein agonists and uses thereof
HK1258695A1 (en) Fmdv and e2 fusion proteins and uses thereof
GB201503218D0 (en) Particles comprising fusion proteins
HK1257937A1 (en) Fusion protein
EP3237452A4 (en) Fusion proteins and methods thereof
HK1251456A1 (en) Immunoglobulin fusion proteins and uses thereof